Industrial medicine views random control trials (RCTs) as the gold standard for determining the efficacy of medications. The thinking goes: blinding, controls/placebos and regular reporting produce objectively reliable, generalizable results. Yet critics argue that RCTs, at least the ones that clinicians habitually read in the reprints of medical journal articles shared by drug company reps, […]
Category Archives: RCTs
Many drugs have no extra benefits for many patients
A new study of recently introduced drugs in Germany finds that many of the drugs confer no appreciable benefit relative to existing drugs: Between 2011 and 2017, IQWiG assessed 216 drugs entering the German market following regulatory approval, they explain. Almost all of these drugs were approved by the European Medicines Agency for use throughout […]
